Services
Biomarkers & cytokines
The company is currently focusing its strategy on protein biomarkers of clinical interest and their applications for in-vitro diagnostic.
Indicia Biotechnology addresses the mutation of the pharmaceutical market in providing a wide range of customized services from biomarker validation to theranostic solutions across many therapeutic areas.
Biomarker analysis contributes to diagnose diseases, to evaluate the efficacy and the safety of drug candidates, to predict or to monitor the response of patients to medications.
Our scope of expertise:
1- Validation of biomarkers (BM)
Indicia Biotechnology provides R&D services to contribute to the validation of key biomarkers (BM):
In this field, Indicia addresses unmet needs by offering cutting edge technologies and high performance technical platforms:
a. Erenna Singulex® (biomarker quantification at the femtogram level),
b. xMAP™ Luminex® (multiplexed assay: panel of biomarkers),
c. ELISA, EIA...
2- Samples bio-analysis during clinical trials
Indicia Biotechnology, as a CRO, helps pharmaceutical companies to accelerate their drug discovery and development process by providing bio-analytical samples testing services during (pre)clinical and no-clinical studies (proof of concept study).(See also our Bioanalysis page)
3- Companion test solution (IVD test)
Indicia can develop, validate and manufacture Companion IVD test in order to:
- select patient (predictive response to the treatment),
- monitor the treatment.
Depending on the sensitivity required, Indicia proposes dedicated technologies (Lateral flow, ELISA, Multiplexed assay, ultrasensitive method…).
(See also Technologies and Companion test pages)